18 and older, any sex, with Covid19 or Critical Care. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)Primary· 6 months after the ICU discharge
The WHODAS 2.0 is a self-reported disability questionnaire based on the International Classification of Functioning, Disability, and Health (ICF). It includes 36 questions, organised under six domains (cognition, mobility, self-care, getting along, life activities and participation). Each question must be answered based on the perceived difficulty for performing activities using a 5-point scale (none, mild, moderate, severe and extreme). The overall score of each domain, it is transformed into a score between 0 and 100, where 0 means no disability and 100 is complete disability
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
5
2 – 18
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
13.5
2 – 23
Clinical Frailty ScaleSecondary· Within 72 hours from ICU discharge
The CFS evaluates specific domains including physical functioning, activities of daily living (ADL), instrumental ADL, assistance for personal care, comorbidities, and cognition to generate a frailty score using a 9-point scale ranging from 1 (very fit) to 9 (terminally ill). A score greater than 4 is considered fragile
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
2
2 – 3
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
3
2 – 3
Medical Research Council Sum Score (MRC-SS): Peripheral Muscle StrengthSecondary· Within 72 hours from ICU discharge
the MRC-SS consists of a standardised examination of six muscle groups bilaterally (i.e. shoulder abduction, elbow flexion, wrist extension, hip flexion, knee extension and dorsiflexion). All muscle groups are scored using a 6-point scale between 0 and 5 (0 = no visible /palpable contraction; 1 = visible / palpable contraction or no limb movement; 2 = limb movement, but not against gravity; 3 = movement against the gravity over nearly the entire range of motion; 4 = motion against gravity and resistance, subjectively adjusted for gender and age; 5 = normal force). The score goes from 0 (no str
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
52
46 – 57
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
50
44 – 57
Functional Status Score for the Intensive Care Unit (FSS-ICU)Secondary· Within 72 hours from ICU discharge
The FSS-ICU is a mobility instrument to score the level of physical assistance required when performing five functional activities: rolling, transfer from supine to sit, sitting at the edge of the bed, transfer from sitting to stand, and walking. Each activity is scored using a 7-point scale ranging from 0 (not able to perform) to 7 (complete independence). The resulting overall score ranges from 0 to 35 points, where a higher scores indicates better performance.
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
26
21 – 32
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
27
19 – 32
Montreal Cognitive Assessment-Blind (MoCA Blind)Secondary· 6 months after the ICU discharge
The MoCA blind is a cognitive screening tool designed to detect cognitive dysfunction in five areas: memory, attention, language, abstraction and orientation. Each domain is scored separately for a total score ranging from 0 to 22 points. A score equal to or greater than 18 points is considered normal cognition.
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
21
19 – 22
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
20
18 – 22
Hospital Anxiety and Depression Scale (HADS)Secondary· 6 months after the ICU discharge
The HADS is an interviewer or self-administered questionnaire designed to identify anxiety and depressive symptoms in a wide variety of in-hospital patients, which requires between 2 and 5 minutes to be completed. The HADS has fourteen questions, seven for anxiety and seven for depressive symptoms. Each question is rated with a 4-point scale ranging from 0 ("absence") to 3 ("extreme presence"), resulting in a sum score of 21 points per subscale. For each subscale, a score \>8 indicates suspected anxiety or depression, while a score \>11 indicates clinical symptoms of anxiety or depression.
Depression subscale
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
7
5 – 8
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
7
5 – 9
Anxiety subscale
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
6
3 – 9
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
7
3 – 10
Impact of Events Scale-Revised (IES-R)Secondary· 6 months after the ICU discharge
The IES-R is an interviewer or self-administered questionnaire designed to measure the subjective distress caused by traumatic events that has been validated for critical illness survivors. It comprises 22 questions in three subscales: intrusion, avoidance, and hyperarousal. Questions are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The score goes from 0 to 88 points. Scores above 33 are indicative of post-traumatic stress symptoms.
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
13.5
5 – 38
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
22
7 – 44
European Quality of Life Health Questionnaire (EQ-5D-3L)Secondary· 6 months after the ICU discharge
The EQ-5D-3L is an interviewer or self-administered questionnaire of health status or health-related quality of life, including five domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression and global health state. Each domain is scored based on 3 levels of severity: no problems, some problems, and extreme problems. Each combination of answers can be translated into a utility score, where 0 is similar to being dead and 1 represents the best possible quality of life. The utility scores were obtained using the Chilean Social valuation of EQ-5D health states (DOI: http:
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
0.79
0.57 – 1.00
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
0.74
0.51 – 0.79
Employment StatusSecondary· 6 months after the ICU discharge
The employment status was evaluated using the following questions: What is your current employment status? What working hours do you have? and has your employment situation changed after your ICU stay?
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
18
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
17
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
3
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
3
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
4
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
9
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
4
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
8
SurvivalSecondary· 6 months after the ICU discharge
Number of patients who survived
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
148
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
95
Cohort Retention RateSecondary· Every month during one year
Number of patients who can be contacted and evaluated
Group
Value
95% CI
Intensive Care Unit Stay During High Bed Occupancy in the COVID-19 Pandemic
30
Intensive Care Unit Stay During Low Bed Occupancy in the COVID-19 Pandemic
37
Sponsor's own description
Intensive care unit (ICU) survivors and their families frequently present mental, cognitive and physical impairments lasting years. The ongoing pandemic could affect the duration, variety, and severity of these impairments. Our aim is to determine the impact of the COVID-19 pandemic on the physical, mental, and cognitive health of survivors, the experience of their families and their treating healthcare professionals in the long-term.
This is a prospective, multicentre, mixed-methods cohort study in seven Chilean ICUs. The perceptions of family members regarding the ICU stay and the later recovery will be explored 3 months after discharge. Health care professionals will be invited to discuss the challenges faced during the pandemic using semi-structured interviews.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix
· EARLY_PHASE1
· active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation
· NA
· recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs
· NA
· active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry
· recruiting
NCT04806061 — Urine Alkalinisation in COVID-19
· NA
· active not recruiting
Other Universidad del Desarrollo trials
Trials by the same sponsor.
NCT06260111 — Photobiomodulation for Oral Mucositis and Functional Impairments During Hematopoietic Stem Cell Transplantation
· NA
· recruiting
NCT05790837 — Workplace Intervention to Reduce Sitting Time: a Randomized Clinical Trial.
· NA
· completed
NCT05393596 — Effects of Virtual Reality Software on Levels of Stigma Towards People With Mental Illness.
· NA
· completed
NCT05291208 — Clinical Trial Through Combined tACS Therapy in Patients With Mild Cognitive Impairment
· Phase 2
· unknown
NCT05425069 — Evaluation of the EEG Connectivity Using Predominant Dexmedetomidine as Anesthetic in Fragile Brains
· unknown
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad del Desarrollo
Last refreshed: 12 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04979897.